US Patent

US11896586 — Apixaban formulations

Method of Use · Assigned to Bristol Myers Squibb Co · Expires 2040-11-22 · 15y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a pharmaceutical formulation of apixaban and its use in treating a thromboembolic disorder.

USPTO Abstract

Apixaban pharmaceutical formulation is provided. Also provided is a use of the apixaban formulation in treatment of a thromboembolic disorder.

Drugs covered by this patent

Eliquis (apixaban) · Bristol-Myers Squibb

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4180`	—	Eliquis

Patent Metadata

Patent number: US11896586
Jurisdiction: US
Classification: Method of Use
Expires: 2040-11-22
Drug substance claim: No
Drug product claim: Yes
Assignee: Bristol Myers Squibb Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.